On 2025‑10‑02, Ambry Genetics, a wholly owned subsidiary of Tempus AI, Inc., announced a new enhancement to its CARE program. The update embeds breast density into the Tyrer‑Cuzick (TC) breast cancer risk score directly within the electronic health record, giving clinicians real‑time, more precise risk estimates at the point of care.
The enhancement offers four TC score options that correspond to BI‑RADs breast density categories (A–D), allowing clinicians to select the most appropriate risk calculation for each patient. The CARE program’s updated scoring has been validated to interpret NCCN guidelines with 99.5% accuracy, and the integration helps health systems move beyond mere compliance with FDA breast density reporting requirements.
By providing a more accurate, workflow‑integrated risk assessment, the update is expected to increase utilization of Ambry’s hereditary testing services, expand the company’s market share in breast cancer screening, and reinforce Tempus’s strategy of delivering AI‑enabled precision diagnostics across oncology and hereditary medicine.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.